Results 221 to 230 of about 74,008 (304)

Multiple Myeloma in a Resource‐Limited Setting: Clinical Presentation, Treatment Patterns, and Outcomes From a 99‐Patient Cohort in Senegal

open access: yeseJHaem, Volume 7, Issue 6, December 2026.
ABSTRACT Background: Therapeutic advances have profoundly improved outcomes in multiple myeloma (MM) in high‐income countries. In sub‐Saharan Africa; however, data remain scarce and access to novel therapies is limited. We aimed to characterize the clinical presentation, treatment strategies, and outcomes of MM patients managed in a resource‐limited ...
Nata Dieng   +7 more
wiley   +1 more source

Beyond binary: graded frailty assessment and outcomes after CAR-T cell therapy in relapsed/refractory multiple myeloma. [PDF]

open access: yesBlood Cancer J
Hashmi H   +14 more
europepmc   +1 more source

Immunophenotypic, Cytogenetic, and Molecular Characterization of NUP98-Rearranged Pediatric Myeloid Neoplasms. [PDF]

open access: yesMod Pathol
Khanlari M   +11 more
europepmc   +1 more source

Real‐World Treatment Patterns, Tolerability, and Outcomes Among Patients With CLL/SLL Treated With First‐Line Ibrutinib, Acalabrutinib, or Zanubrutinib in the US Community Oncology Setting: A Retrospective Cohort Study

open access: yeseJHaem, Volume 7, Issue 6, December 2026.
ABSTRACT Background Covalent Bruton tyrosine kinase inhibitors (cBTKis) are standard first‐line (1L) therapies for chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL). In clinical trials, second‐generation (2G) cBTKis demonstrated better tolerability than ibrutinib, particularly regarding cardiotoxicity; however, real‐world evidence on ...
John M. Burke   +10 more
wiley   +1 more source

Identification of a Novel KRAS::ETNK1 Fusion Transcript in a Myelodysplastic/Myeloproliferative Overlap Syndrome With Eosinophilia: A Case Report

open access: yeseJHaem, Volume 7, Issue 6, December 2026.
ABSTRACT This work describes, to our knowledge, the first reported case of a patient with an MDS/MPN overlap syndrome harboring a novel KRAS::ETNK1 fusion transcript. The disease initially presented with eosinophilia, megakaryocyte expansion, mast cell infiltration, and a background of typical MDS/MPN‐associated mutations (ASXL1, TET2, EZH2, BCOR, and ...
Marianne Caledec   +17 more
wiley   +1 more source

Comparison of venetoclax and azacitidine versus a cytarabine-based treatment for patients with acute myeloid leukaemia in first relapse after chemotherapy. A real-world study of the DATAML-IPC-AURAML consortium. [PDF]

open access: yesBr J Haematol
Dumas PY   +22 more
europepmc   +1 more source

Gemtuzumab Ozogamicin for Patients with Newly Diagnosed CD33‐Positive Acute Myeloid Leukemia: A French Retrospective Observational Study

open access: yeseJHaem, Volume 7, Issue 6, December 2026.
ABSTRACT Introduction Gemtuzumab ozogamicin (GO), a CD33‐targeted antibody–drug conjugate, is approved in combination with daunorubicin/cytarabine for patients ≥ 15 years with de novo, CD33‐positive acute myeloid leukemia (AML). Methods This retrospective, observational study assessed real‐world use, clinical outcomes, and safety of GO in 113 patients ...
Juliette Lambert   +8 more
wiley   +1 more source

Home - About - Disclaimer - Privacy